IVANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as IVEVF
Inventiva S.A.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 8, 2026
$2.98+0.04 (+1.36%)
Close on Oct 19, 2026
Inventiva S.A. revenue by segment
By business segment
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| China | €4.48M | €9.13M | €4.61M | €12.05M | – | – | 100.0% | -50.9% |
| France | – | €69.00K | €118.00K | €127.00K | €194.00K | €372.00K | – | – |
| United States | – | – | – | -€2.00K | €4.00M | – | – | – |
| Japan | – | – | €12.75M | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Inventiva's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.